12:00 AM
 | 
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Tivantinib: Completed Phase III enrollment

ArQule and Daiichi Sankyo completed enrollment in the double-blind, international Phase III MARQUEE trial comparing twice-daily 360 mg oral tivantinib plus daily 150 mg oral Tarceva erlotinib vs. placebo plus Tarceva in about 1,000 patients with locally advanced or metastatic NSCLC who received 1-2...

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >